Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;15(4):204-206.

Use of Vedolizumab for the Treatment of Crohn's Disease

Brian Bressler  1
Affiliations

Use of Vedolizumab for the Treatment of Crohn's Disease

Brian Bressler. Gastroenterol Hepatol (N Y). 2019 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr Bressler has served as an advisor/speaker for Shire, Ferring, Janssen, AbbVie, Takeda, Actavis, Pfizer, and Novartis; has served as an advisor for Robarts Clinical Trials, Celgene, Microbiome Insights, Merck, Amgen, Pendopharm, Genentech, Celltrion, Allergan, and Protagonist; and has received research support from Janssen, AbbVie, GSK, BMS, Amgen, Genentech, Merck, RedHill Biopharma, BI, Qu Biologics, Celgene, and Alvine.

References

    1. Colombel JF, Sands BE, Rutgeerts P et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–851. - PMC - PubMed
    1. Feagan BG, Lasch K, Lissoos T et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(1):130–138.e7. - PubMed
    1. Lam MC, Bressler B. Vedolizumab for ulcerative colitis and Crohn’s disease: results and implications of GEMINI studies. Immunotherapy. 2014;6(9):963–971. - PubMed
    1. Sandborn WJ, Feagan BG, Rutgeerts P et al. GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721. - PubMed
    1. Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627.e3. - PubMed

LinkOut - more resources